Lyell Immunopharma (LYEL) Leases (2020 - 2025)
Lyell Immunopharma (LYEL) has disclosed Leases for 6 consecutive years, with $18.9 million as the latest value for Q4 2025.
- Quarterly Leases fell 23.72% to $18.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.9 million through Dec 2025, down 23.72% year-over-year, with the annual reading at $18.9 million for FY2025, 23.72% down from the prior year.
- Leases hit $18.9 million in Q4 2025 for Lyell Immunopharma, down from $19.9 million in the prior quarter.
- In the past five years, Leases ranged from a high of $48.4 million in Q2 2021 to a low of $18.9 million in Q4 2025.
- Historically, Leases has averaged $37.1 million across 5 years, with a median of $40.6 million in 2023.
- Biggest five-year swings in Leases: fell 1.0% in 2021 and later crashed 45.69% in 2025.
- Year by year, Leases stood at $46.5 million in 2021, then fell by 7.09% to $43.2 million in 2022, then decreased by 8.28% to $39.7 million in 2023, then plummeted by 37.63% to $24.7 million in 2024, then dropped by 23.72% to $18.9 million in 2025.
- Business Quant data shows Leases for LYEL at $18.9 million in Q4 2025, $19.9 million in Q3 2025, and $21.0 million in Q2 2025.